The Broad Institute in Massachusetts, US will provide computational modelling support for a joint research project between Pfizer and EMD Serono profiling the genomes of lupus patients.

The goal of the collaboration is to find diagnostic approaches for disease monitoring and hone patient recruitment for future clinical studies, a spokeswoman from EMD Serono told Outsourcing-Pharma.com.

The project, jointly funded by EMD Serono and Pfizer, will investigate Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN). SLE is a systemic autoimmune disease which can lead to LN, an inflammation of the kidney. SLE affects the kidneys, skin, nervous system, and joints.

Immune cell subpopulations in the samples will be analysed at the Broad Institute’s facility and the genomic data generated will be worked up both by Broad and independently by EMD Serono and Pfizer, she said.

The objective is to identify which molecules drive SLE and LN kidney flares, helping scientists tailor new drugs.

The research also aims to identify biomarkers which will allow drug makers to target specific patient populations for future therapies.

Real-time access

As sponsors, EMD Serono and Pfizer will receive real-time access to all data and analysis, Buffington told Outsourcing-Pharma.com.

“EMD Serono and Pfizer are providing the financial support for this research program. The computational modelling will be done by the Broad Institute, but we will have access to all raw data and we will also do some of our own analysis.”

Both companies have the option to send a research scientist to the Broad Institute to exchange expertise in computational and experimental genomic profiling.

The Broad Institute
is a not-for-profit biomedical and genomic research centre in Cambridge, Massachusetts, with affiliations to Harvard University and the Massachusetts Institute of Technology.